We are live on
!
Find out more
MU
Mirova US Portfolio holdings
AUM
$8.81B
1-Year Est. Return
21.38%
This Fund
S&P 500
This Quarter
Est. Return
-4.9%
1 Year Est. Return
+21.38%
3 Year Est. Return
+80.7%
5 Year Est. Return
+106.85%
10 Year Est. Return
–
AUM
$8.81B
AUM Growth
-$1.15B
(-12%)
Cap. Flow
-$427M
Cap. Flow
% of AUM
-4.85%
Top 10 Holdings %
Top 10 Hldgs %
49.97%
Holding
43
New
–
Increased
6
Reduced
32
Closed
1
Top Buys
| 1 |
Boston Scientific
BSX
|
+$66.7M |
| 2 |
Veralto
VLTO
|
+$60.5M |
| 3 |
Broadcom
AVGO
|
+$60.5M |
| 4 |
Vertiv
VRT
|
+$53.5M |
| 5 |
AGCO
AGCO
|
+$51.2M |
Top Sells
| 1 |
Visa
V
|
+$144M |
| 2 |
TSMC
TSM
|
+$137M |
| 3 |
Roper Technologies
ROP
|
+$86.2M |
| 4 |
Ecolab
ECL
|
+$75.5M |
| 5 |
First Solar
FSLR
|
+$42.1M |
Sector Composition
| 1 | Technology | 36.34% |
| 2 | Industrials | 20.12% |
| 3 | Healthcare | 16.18% |
| 4 | Consumer Discretionary | 12.08% |
| 5 | Financials | 6.61% |
Similar funds
MERSOM
CFB
MOACM
SWP
CB
WT
OAM
PEA
Mirova US's Q1 2026 Portfolio in Review
As of Q1 2026, Mirova US held 43 positions worth $8.81B, down 12% from $9.96B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Mirova US withdrew a net $427M in Q1 2026, closing 1 position and reducing 32 holdings. Its most notable exit was Roper Technologies, an estimated $86.2M position sold in full.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 41% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Mirova US added an estimated $66.7M to Boston Scientific.
- Mirova US added most to Boston Scientific in Q1 2026, an estimated $66.7M increase.
- Mirova US's biggest Q1 2026 reduction was Visa, cutting an estimated $144M.
- Mirova US fully exited Roper Technologies in Q1 2026, selling an estimated $86.2M.
- Mirova US's ten largest holdings make up 50% of its $8.81B portfolio in Q1 2026.
- Mirova US opened 0 new positions and closed 1 in Q1 2026.
- Mirova US's portfolio value fell 12% quarter-over-quarter to $8.81B.
Based on Mirova US's 13F filing for Q1 2026, filed 11 May 2026.